Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Adaptimmune Therapeutics plc (473A.F)

0.2180
+0.0290
+(15.34%)
At close: April 25 at 3:49:30 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Adrian G. Rawcliffe CEO, Principal Accounting Officer & Director 914.74k -- 1972
Mr. William C. A. Bertrand Jr., Esq., J.D. COO & Chief Compliance Officer 616.48k -- 1965
Ms. Cintia Piccina Pharm.D. Chief Commercial Officer 447.62k -- 1973
Dr. Helen Katrina Tayton-Martin MBA, Ph.D. Co-Founder 593.95k -- 1967
Ms. Joanna Brewer Ph.D. Chief Scientific Officer -- -- 1976
Dr. Juli P. Miller Ph.D. VP of Corporate Affairs & Investor Relations -- -- --
Ms. Kerry Sharp Senior VP & General Council -- -- --
Ms. Dana Lynch Senior Director of Corporate Communications -- -- --
Mr. John Lunger Chief Patient Supply Officer 566.34k 129.94k 1969
Dr. Elliot Norry B.A., M.D. Chief Medical Officer 592.89k 57.01k 1963

Adaptimmune Therapeutics plc

60 Jubilee Avenue
Milton Park
Abingdon, OX14 4RX
United Kingdom
44 12 3543 0000 https://www.adaptimmune.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
506

Description

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Corporate Governance

Adaptimmune Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 13, 2025 at 8:00 PM UTC - May 17, 2025 at 8:00 PM UTC

Adaptimmune Therapeutics plc Earnings Date

Recent Events

Related Tickers

2105.HK Laekna, Inc.
13.660
-6.18%
 
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
293.800
-4.67%
 
9969.HK InnoCare Pharma Limited
10.140
-3.61%
 
SION Sionna Therapeutics, Inc.
12.14
-3.65%
 
1672.HK ASCLETIS-B
6.280
-6.69%
 
ALXO ALX Oncology Holdings Inc.
0.5417
-9.87%
 
EWTX Edgewise Therapeutics, Inc.
14.84
-3.64%
 
9926.HK Akeso, Inc.
98.900
-1.10%
 
CYTK Cytokinetics, Incorporated
40.43
+0.25%
 
DYN Dyne Therapeutics, Inc.
11.06
-0.45%